Lista de obras - Eva Havrdová - Dominio Público Uruguay

A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS

scientific article published on 28 February 2019

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

artículo científico publicado en 2016

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.

artículo científico publicado en 2013

Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium

artículo científico publicado en 2020

Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis.

artículo científico publicado en 2016

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

artículo científico publicado en 2014

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis

artículo científico publicado en 2015

Contribution of different relapse phenotypes to disability in multiple sclerosis.

artículo científico publicado en 2016

Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome

artículo científico publicado en 2012

Cross cultural validation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) and the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS).

artículo científico publicado en 2012

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

artículo científico publicado en 2015

Defining secondary progressive multiple sclerosis

artículo científico publicado en 2016

Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience

artículo científico publicado en 2015

Detection of cortical lesions is dependent on choice of slice thickness in patients with multiple sclerosis

artículo científico publicado en 2007

Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: results of a 5-year follow-up study.

artículo científico publicado en 2013

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

artículo científico publicado en 2011

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

artículo científico publicado en 2009

Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study

artículo científico publicado en 2013

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

artículo científico publicado en 2015

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison

artículo científico publicado en 2013

Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study

artículo científico publicado en 2013

Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study

artículo científico publicado en 2009

Health-related quality of life in multiple sclerosis: effects of natalizumab

artículo científico publicado en 2007

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.

artículo científico publicado en 2016

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

artículo científico publicado en 2016

Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: results from the multi-center set study

artículo científico publicado en 2014

Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later.

artículo científico publicado en 2015

Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes

artículo científico publicado en 2013

Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event

artículo científico publicado en 2013

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis

artículo científico publicado en 2017

Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel

artículo científico publicado en 2014

Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ.

artículo científico publicado en 2017

Natalizumab promotes anti-inflammatory and repair effects in multiple sclerosis

artículo científico publicado en 2024

Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report

artículo científico publicado en 2007

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.

artículo científico publicado en 2018

Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Me

artículo científico

Oral BG-12 in multiple sclerosis

artículo científico publicado en 2013

Patients' stratification and correlation of brain magnetic resonance imaging parameters with disability progression in multiple sclerosis

artículo científico publicado en 2009

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

artículo científico publicado en 2012

Predictors of long-term disability accrual in relapse-onset multiple sclerosis

artículo científico publicado en 2016

Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program

scientific article published on 13 July 2016

Real-Life Outcome in Multiple Sclerosis in the Czech Republic

artículo científico publicado en 2019

Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment

artículo científico publicado en 2014

Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study

artículo científico publicado en 2016

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

artículo científico publicado en 2012

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study

artículo científico publicado en 2014

Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study

artículo científico publicado en 2014

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

artículo científico publicado en 2015

The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis

artículo científico publicado en 2016

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

artículo científico publicado en 2015

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

artículo científico publicado en 2009

Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations

artículo científico publicado en 2005

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

artículo científico publicado en 2017

Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study

artículo científico publicado en 2012

Lista de obras de Eva Havrdová

A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.

Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium

Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis.

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis

Contribution of different relapse phenotypes to disability in multiple sclerosis.

Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome

Cross cultural validation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) and the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS).

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Defining secondary progressive multiple sclerosis

Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience

Detection of cortical lesions is dependent on choice of slice thickness in patients with multiple sclerosis

Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: results of a 5-year follow-up study.

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison

Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study

Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study

Health-related quality of life in multiple sclerosis: effects of natalizumab

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: results from the multi-center set study

Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later.

Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes

Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis

Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel

Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ.

Natalizumab promotes anti-inflammatory and repair effects in multiple sclerosis

Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.

Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Me

Oral BG-12 in multiple sclerosis

Patients' stratification and correlation of brain magnetic resonance imaging parameters with disability progression in multiple sclerosis

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

Predictors of long-term disability accrual in relapse-onset multiple sclerosis

Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program

Real-Life Outcome in Multiple Sclerosis in the Czech Republic

Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment

Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study

Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study